Divalproex Sodium Tablet, Delayed Release
Product Images NDC 60760-798

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 60760-798). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

798-60 (Divalproex 60760 798 60)

Label for Divalproex Sodium delayed-release tablets, USP 500 mg, with valproic acid activity. The label indicates a quantity of 60 tablets. Manufactured by Sun Pharmaceutical Industries Ltd., India, and packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label includes NDC 60760-798-60 and instructions to store at controlled room temperature 15°-30°C (59°-86°F).*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

Bar graph comparing percentages of two studies labeled Study 1 (YMRS) and Study 2 (MRS). Each study has two bars: one for PBO with percentages around 26-29%, and one for DVPX with higher percentages around 58-60%, marked with an asterisk indicating significance. The vertical axis shows percentage values from 0% to 70%.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A cumulative distribution plot comparing the percentage reduction in CPS rate between Divalproex Sodium (DVPX) and placebo groups. The y-axis shows percent reduction in CPS rate from -100% to 100%, with direction indicators for improvement or worsening. The x-axis shows percentage of patients, ranging from 100% to 0%, with DVPX represented by a solid line and placebo by a dashed line.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A line graph titled Figure 3 displaying the percent reduction in CPS rate on the vertical axis versus the percent of patients on the horizontal axis. The graph compares two dose groups, high dose and low dose, with lines showing changes ranging from -100% to +100% indicating worsening to improvement in CPS rate across patient percentages.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar chart titled 'Mean 4-week Migraine Rates' comparing migraine rates in two studies. Each study shows migraine rates for two groups: Placebo and Divalproex Sodium (DVPX). The chart presents higher mean migraine rates with placebo than with Divalproex Sodium in both Study 1 and Study 2.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure of divalproex sodium, depicting the molecular arrangement including sodium ion and valproate moieties as a repeating polymer unit.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.